Riham Suleiman

Dr. Riham Suleiman

Mayo Clinic, Rochester, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2024 in Cancer Reports
Verified
Journal Article
Open access
Riham SuleimanRiham Suleiman
Riham Suleiman
PMPatrick McGarrah
Patrick McGarrah
BBBinav Baral
Binav Baral
DODawn Owen
Dawn Owen
JAJesus Vera Aguilera
Jesus Vera Aguilera
HFHarry Fuentes-Bayne
Harry Fuentes-Bayne
Background: Recurrent squamous cell carcinoma (SCC) of the head and neck (SCCHN) remains a formidable clinical challenge despite available treatments. The phosphatidylinositol 3‐kinase (PI3K) pathway has been identified as a potential therapeutic target, and alpelisib, a selective PI3Kα inhibitor, has demonstrated efficacy in certain malignancies. Combining this targeted therapy with immunotherapy has been suggested in previous studies as a promising strategy to bolster the immune response against cancer.Cases: A 69‐year‐old woman with locoregional recurrence of PIK3CA‐mutated SCC of the left maxilla and cervical nodal metastases. Several chemotherapeutic regimens, including cisplatin, docetaxel, 5FU, chemoradiotherapy, and mono‐immunotherapy, resulted in disease progression. Alpelisib combined with pembrolizumab led to a sustained response for 9 months. A 58‐year‐old man with recurrent metastatic PIK3CA‐mutated SCC of the oropharynx, involving the left lung, hilar, and mediastinal lymph nodes. Despite prior palliative radiation and platinum‐based chemotherapy with pembrolizumab and cetuximab, treatment with alpelisib and nivolumab resulted in a partial response. Severe hyperglycemia and rash led to treatment discontinuation.Conclusion: Our findings highlight the potential of this innovative therapeutic combination, suggesting a need for further investigations in this setting.

23 July 2025 in ESMO Open
Verified
Journal Article
Open access
HFHarry Fuentes-Bayne
Harry Fuentes-Bayne
Riham SuleimanRiham Suleiman
Riham Suleiman
RER.A. Eiring
R.A. Eiring
PMPatrick W McGarrah
Patrick W McGarrah
STS.D. Thome
S.D. Thome
THT.R. Halfdanarson
T.R. Halfdanarson
Cancer of unknown primary (CUP) remains a diagnostic and therapeutic challenge with limited treatment guidance. Caudal type homeobox 2 (CDX2), a transcription factor indicative of intestinal differentiation, may define a distinct subset of CUP with potential sensitivity to 5-fluorouracil (5-FU)-based chemotherapy. This study examines outcomes in patients with CDX2-positive CUP and the predictive value of CDX2 expression for response to 5-FU-based regimens. We analyzed data from CDX2-positive CUP patients in the Mayo Clinic Cancer of Unknown Primary registry. All patients underwent comprehensive diagnostic evaluations and received first-line systemic therapy, categorized as 5-FU-based or non-5-FU-based. Primary endpoints were objective response rate (ORR) and clinical benefit rate; secondary endpoints included progression-free survival at first progression (PFS1) and overall survival. Logistic and Cox regression models were used to identify predictors of ORR and survival. A total of 209 CDX2-positive CUP patients met inclusion criteria. The median age was 64 years (range 18-89 years), with 115 (55%) female patients. Adenocarcinoma was the predominant histology in 147 patients (74.7%), while only 39 (18.7%) exhibited the classical colorectal-like immunoprofile (CK7-negative/CK20-positive/CDX2-positive). Most patients (203, 97.1%) had multiple metastatic sites, and 98 (46.9%) received 5-FU-based chemotherapy regimens. 5-FU-Based treatment was associated with a significantly higher ORR compared with non-5-FU regimens [68 of 98 (69.4%) versus 53 of 111 (47.7%), P = 0.002], as well as higher clinical benefit rate [84 of 98 (85.7%) versus 80 of 111 (72.1%), P = 0.017]. Multivariable logistic regression identified 5-FU use as the only independent predictor of response (OR 2.28, 95% confidence interval 1.23-4.23, P = 0.009). Median overall survival was longer in the 5-FU group compared with non-5-FU (21.0 versus 14.0 months, P = 0.008), as was median PFS1 (15.2 versus 6.3 months, P < 0.001). Multivariable Cox regression confirmed 5-FU therapy as an independent prognostic factor for longer PFS1 (hazard ratio 0.50, 95% confidence interval 0.31-0.80, P = 0.004). CDX2-positive CUP represents a distinct subgroup with favorable response to 5-FU-based therapy, supporting CDX2 as a predictive biomarker for treatment selection.

15 November 2022 in Clinical Case Reports
Verified
Journal Article
Open access
Riham SuleimanRiham Suleiman
Riham Suleiman
DADema Adwan
Dema Adwan
MSMhd Firas Safadi
Mhd Firas Safadi
A 25‐year‐old woman presented to the emergency department with acute abdominal pain and amenorrhea. The vaginal ultrasound showed a right para‐adnexal mass with a living embryo. An abdominal pregnancy on the ascending colon was found in the laparotomy. The management included removing the gestational sac and treatment with methotrexate.

1 September 2023 in JCO Precision Oncology
Verified
Journal Article
Closed access
SASandra Algarin-Perneth
Sandra Algarin-Perneth
Riham SuleimanRiham Suleiman
Riham Suleiman
JAJithma P. Abeykoon
Jithma P. Abeykoon
Thorvardur HalfdanarsonThorvardur Halfdanarson
Thorvardur Halfdanarson
HFHarry E. Fuentes-Bayne
Harry E. Fuentes-Bayne
PMPatrick W McGarrah
Patrick W McGarrah
Metastatic CUP is complex, especially NCUP. Precision oncology is crucial for rare, aggressive cancers. A 54-year-old had HER2+ neuroendocrine carcinoma of unknown origin. T-DXd treatment, response, re-challenge show importance of genomics and caution.

2 June 2026 in The Oncologist
Verified
Journal Article
Open access
Riham SuleimanRiham Suleiman
Riham Suleiman
RGRay Guo
Ray Guo
MLMary E Lohman
Mary E Lohman
STStephan D Thome
Stephan D Thome
LPLance C Pagliaro
Lance C Pagliaro
HFHarry Fuentes-Bayne
Harry Fuentes-Bayne
Background: Extramammary Paget disease (EMPD) is a rare cutaneous adenocarcinoma. While localized disease has an excellent prognosis, metastatic EMPD is aggressive with no standardized systemic therapy. This study characterizes the clinicopathologic and molecular landscape of metastatic/recurrent EMPD to identify therapeutic vulnerabilities. Patients and methods: We conducted a retrospective cohort study of 26 patients with metastatic or distantly recurrent EMPD treated at Mayo Clinic (2000-2025). Descriptive statistics were used to summarize baseline characteristics. Survival outcomes were estimated using Kaplan–Meier methods, with group comparisons performed using log-rank testing. Continuous variables were compared using nonparametric tests, and categorical variables were analyzed using appropriate comparative tests. Pathway-level genomic correlations with TCGA reference cohorts were assessed using Spearman rank correlation. Treatment responses were retrospectively evaluated from radiologic reports. Results: The cohort was predominantly male (73.1%) and White (92.3%), with a median age of 68 (IQR, 53-79). Lymph nodes were the most common metastatic site (61.5%). The median overall survival (OS) was 20.0 months (95% CI, 0-40.4). IHC showed universal CK7 and GATA3 positivity, with 80% androgen receptor (AR) expression. HER2 was positive (3+) or amplified in approximately one-third of cases. NGS revealed frequent mutations in TP53 (68.8%), ERBB2 (50%), and CDKN2A/B (50%). A “triple-hit” deletion at the 9p21 locus (CDKN2A/B/MTAP) was identified in 25% of cases. Genomic profiling showed strong similarity to HER2+ breast and urothelial carcinomas. HER2-directed therapy was associated with longer overall survival (median OS 73.0 months [95% CI, 0-177.9] vs 19.0 months [95% CI, 0-41.4]; HR 0.50 [95% CI, 0.0-177.9], P = .3), although this difference did not reach statistical significance. Conclusion: Metastatic EMPD exhibits distinct clinicopathologic and molecular features, including high AR and HER2 expression, TP53 and CDKN2A/B alterations, and similarity to systemic HER2+ malignancies. The observed activity of HER2-directed therapies in this cohort suggests the potential value of further investigating biomarker-guided treatment strategies in metastatic EMPD. NGS-guided profiling may inform precision treatment strategies, including AR-targeted therapy and emerging MTAP-directed approaches.

22 June 2026 in ESMO Rare Cancers
Verified
Journal Article
Open access
Riham SuleimanRiham Suleiman
Riham Suleiman
RGR. Guo
R. Guo
NVN.Y. Vidal
N.Y. Vidal
MLM.E. Lohman
M.E. Lohman
LYL.X. Yin
L.X. Yin
HFHarry Fuentes-Bayne
Harry Fuentes-Bayne